Form 4: Immix Biopharma CFO Gabriel Morris Reports Ownership Changes Following Merger

CFO Gabriel Morris reports changes in beneficial ownership of Immix Biopharma stock following the merger with Nexcella, Inc.

Summary

• Gabriel Morris, CFO of Immix Biopharma, filed a Form 4 detailing changes in his beneficial ownership of the company's stock on May 20, 2024.
• The changes are a result of the merger between Immix Biopharma and Nexcella, Inc., where Morris exchanged shares of Nexcella for Immix Biopharma shares.
• Morris directly acquired 194,218 shares and disposed of 280,034 shares of common stock.
• He also indirectly acquired 24,141 shares each through Alwaysraise LLC and Alwaysraise Ventures I, LP.
• After the transactions, Morris directly owns 280,034 shares, indirectly owns 270,844 shares through Alwaysraise LLC, and indirectly owns 24,141 shares through Alwaysraise Ventures I, LP.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing reflecting a routine transaction (merger). It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Mergers and acquisitions frequently trigger these filings as ownership structures change.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership changes resulting from the merger.

Key Dates